title: The potential role of appetite in predicting weight changes during treatment with olanzapine.
abstract: BACKGROUND
  Clinically significant weight gain has been reported during treatment with atypical antipsychotics. It has been suggested that weight changes in patients treated with olanzapine may be associated with increased appetite.
  
  
  METHODS
  Data were used from adult patients for whom both appetite and weight data were available from 4 prospective, 12- to 24-week clinical trials. Patients' appetites were assessed with Eating Behavior Assessment (EBA, Study 1), Platypus Appetite Rating Scale (PARS, Study 2), Eating Inventory (EI, Study 3), Food Craving Inventory (FCI, Study 3), and Eating Attitude Scale (EAS, Study 4).
  
  
  RESULTS
  In Studies 1 (EBA) and 4 (EAS), patients who reported overall score increases on appetite scales, indicating an increase in appetite, experienced the greatest overall weight gains. However, in Studies 2 (PARS) and 3 (EI, FCI), patients who reported overall score increases on appetite scales did not experience greater weight changes than patients not reporting score increases. Early weight changes (2-4 weeks) were more positively correlated with overall weight changes than early or overall score changes on any utilized appetite assessment scale. No additional information was gained by adding early appetite change to early weight change in correlation to overall weight change.
  
  
  CONCLUSIONS
  Early weight changes may be a more useful predictor for long-term weight changes than early score changes on appetite assessment scales.
  
  
  BACKGROUND
  This report represents secondary analyses of 4 clinical studies. Studies 1, 2, and 3 were registered at http://clinicaltrials.gov/ct2/home, under NCT00190749, NCT00303602, and NCT00401973, respectively. Study 4 predates the registration requirements for observational studies that are not classified as category 1 observational studies.
authors.affiliation: Lilly USA, LLC, Indianapolis, IN, USA. case_michael@lilly.com
authors.forename: Michael
authors.initials: M
authors.lastname: Case
authors.forename: Tamas
authors.initials: T
authors.lastname: Treuer
authors.forename: Jamie
authors.initials: J
authors.lastname: Karagianis
authors.forename: Vicki Poole
authors.initials: VP
authors.lastname: Hoffmann
mesh_terms: D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D001066:Appetite / Q000187:drug effects* / Q000502:physiology; D001069:Appetite Regulation / Q000187:drug effects; D001569:Benzodiazepines / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use*; D017327:Clinical Trials, Phase IV as Topic / Q000706:statistics & numerical data; D005247:Feeding Behavior / Q000187:drug effects; D005260:Female; D006801:Humans; D008019:Life Style; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D011336:Probability; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000523:psychology; D012559:Schizophrenia / Q000188:drug therapy; D012565:Schizophrenic Psychology; D015430:Weight Gain / Q000187:drug effects* / Q000502:physiology
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D000077152:Olanzapine